Onconetix, Inc. Files 8-K/A Amendment on Officer/Director Changes

TL;DR

Onconetix filed an 8-K/A amendment covering director/officer changes and financial exhibits.

AI Summary

Onconetix, Inc. filed an amendment (8-K/A) on June 14, 2024, to a previous report dated June 10, 2024. The amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. It also includes financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.

Risk Assessment

Risk Level: medium — Amendments to 8-K filings, especially those concerning leadership and financial statements, can signal underlying issues or significant corporate actions that warrant closer scrutiny.

Key Players & Entities

• Onconetix, Inc. (company) — Registrant
• June 10, 2024 (date) — Earliest event reported date
• June 14, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 001-41294 (company_id) — SEC file number
• Blue Water Biotech, Inc. (company) — Former company name
• Blue Water Vaccines Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.00001 — ch Registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
• $15,000 — Officer of the Company and will be paid $15,000 per month for up to 80 hours of monthly
• $2,500 — and will provide signatory services for $2,500 per month. The Fedasz Consulting Agreem

Filing Documents

• ea0207933-8ka1_onconet.htm (8-K/A) — 38KB
• ea020793301ex10-1_onconet.htm (EX-10.1) — 56KB
• 0001213900-24-052976.txt ( ) — 278KB
• onco-20240610.xsd (EX-101.SCH) — 3KB
• onco-20240610_lab.xml (EX-101.LAB) — 33KB
• onco-20240610_pre.xml (EX-101.PRE) — 22KB
• ea0207933-8ka1_onconet_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 Onconetix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41294 83-2262816 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 201 E. Fifth Street , Suite 1900 Cincinnati , Ohio 45202 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (513) 620-4101 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Explanatory Note On June 13, 2024, Onconetix, Inc. (the " Company ") filed a Current Report on Form 8-K (the " Original 8-K ") to report the appointment of Karina M. Fedasz as the Company's Interim Chief Financial Officer, effective June 10, 2024. This amendment is being filed to amend the Original 8-K to include the terms of Ms. Fedasz's compensation, as approved by the Compensation Committee of the Company's Board of Directors. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with Ms. Fedasz's appointment as Interim Chief Financial Officer, on June 10, 2024, the Company and Ms. Fedasz entered into a consulting agreement (the " Fedasz Consulting Agreement "), pursuant to which Ms. Fedasz will serve as Interim Chief Financial Officer of the Company and will be paid $15,000 per month for up to 80 hours of monthly service to the Company and will provide signatory services for $2,500 per month. The Fedasz Consulting Agreement is for a term of one year, subject to early termination by either party upon thirty (30) days' written notice. The foregoing description of the Fedasz Consulting Agreement is qualified in its entirety by reference to the text of such agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K/A and incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Consulting Agreement, dated June 10, 2024, between the Company and Karina Fedasz. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Onconetix, Inc. Date: June 14, 2024 By: /s/ Ralph Schiess Ralph Schiess Interim Chief Executive Officer 2

View Full Filing

View this 8-K/A filing on SEC EDGAR